When: Close below $396.71 (50 SMA) on volume >4M shares OR intraday low below $389 on volume >5M shares

Then: Execute 30% trim of AMGN

Trim 25% on relief bounce into 405-415 zone with stop at 430; do not increase trim to 40-50%, do not add tactical short, do not wait passively

• The trader's 25% trim plan accounts for technical damage without panic-selling or doubling down on bearish exposure
• Aggressive plan (40-50% trim + tactical short with stop above 430) is concentration risk disguised as aggression that double-counts the same bearish view
• Dividend yield of 2.56% compounds meaningfully over 2-5 year holding period for olpasiran clarity; defensive characteristics explain why stock absorbed 10% single-day drop without breaking 200 SMA uptrend
• 200 SMA at 354.80 is 9% below current price with 2026 uptrend from 321 structurally intact, indicating long-term holders not panicking
• Pelacarsen read-through to olpasiran is not a confirmed hypothesis-killer: olpasiran is GalNAc-conjugated siRNA vs pelacarsen's antisense oligonucleotide mechanism, with OCEAN(a) designed to test whether reduction magnitude matters
• Stop at 430 is correct as it sits above gap-down reference close at 437 and 10 EMA at 422; if price reclaims these levels on volume, breakdown is invalidated
• 2025 net income of $7.71 billion up 88% YoY with operating margin recovering 300 basis points from Horizon integration trough
• TTM free cash flow is $8.65 billion; company has paid down $8.2 billion of net debt from 2023 peak
• Forward P/E of 16x is reasonable for pharma with this growth trajectory; Imdelltra's 115% sales growth and Tezspire Phase III CROSSING win are concrete fundamentals providing support

→ vs aggressive: 40-50% trim plus tactical short double-counts bearish view and creates two-way loss risk if relief bounce extends—stopped out on short AND missed trim window on long

→ vs aggressive: Dismissal of dividend yield (2.56%) and defensive characteristics as meaningless ignores compounding: 5%+ over 2 years, 13% over 5 years, plus 0.43 beta portfolio anchor value

→ vs aggressive: Treating pelacarsen read-through as confirmed olpasiran failure is confident extrapolation, not clinical judgment; Barclays 'worst possible outcome' framing is sell-side news cycle commentary, not clinical assessment; trader's plan already strips 15-30 dollars of olpasiran NPV

→ vs neutral: Waiting for management commentary is the worst of both worlds—underperforms trim if reassuring (8-12% rally) and underperforms current levels if cautious (additional 5-10% selloff); patience with broken technicals is deferred decision-making with same downside exposure

Ratify SELL decision with three modifications: (1) increase trim to 30-35% of existing exposure with execution triggers for both bounce and no-bounce scenarios, (2) maintain stop at 430 and add defined re-entry framework for remaining 65-70% position if breakdown reverses, (3) reject tactical short overlay. Reject both aggressive analyst's 40-50% trim plus short and conservative analyst's passive 25% trim as binary positioning that fails to price all available information.

• Technical damage is real and cannot be hand-waved: MACD rolled from plus 17.87 to plus 5.37 in two weeks, histogram negative 6.68, close below lower Bollinger Band at 391 versus band at 395, gap-down on 2x volume
• Olpasiran NPV was $15-30 per share but the stock dropped $44 per share, suggesting overshooting on the fundamental shift
• Aggressive analyst incorrectly anchors short entry at spot price of 391, which embeds the assumption that today's close is the right price for new information
• 30-35% trim on a 0.43 beta stock is functionally equivalent to 45-50% trim on a beta-1.0 stock, close to aggressive analyst's instinct without concentrated short overlay
• 50 SMA at 396.71 is the operative support level; if it fails, next test is 200 SMA at 354.80
• Polymarket shows 93% probability of no Fed rate cuts in 2026, up 4 percentage points on the week; stagflationary environment expands discount rate on long-duration pharma pipeline assets
• Downside execution trigger: if price closes below 50 SMA at 396.71 on volume exceeding 4 million shares, or intraday low prints below 389 on volume exceeding 5 million shares, execute trim at market regardless of price level
• If price reclaims 430 on volume, breakdown is invalidated; do not add back the trim, let remaining 65-70% ride and reassess on next earnings cycle
• If price drifts to 355 and holds, opportunity to add back up to 80% of original position size on confirmed stabilization above 360 with three consecutive higher lows
• Imdelltra's 115% growth and Tezspire's Phase III win are real but not currently the operative floor; marginal seller is anchoring on olpasiran pipeline NPV impact, not positive catalysts
• Conservative analyst's framework has no defined response to continued technical deterioration; a plan that only tells you what to do if price goes up is not a complete risk management plan

→ vs aggressive: MACD rolling over (plus 17.87 to plus 5.37 in two weeks, histogram negative 6.68) and close below lower Bollinger Band at 391 versus band at 395 is a real price event that cannot be hand-waved, but claiming the entire Lp(a) class is dead on day two of a class-level repricing event is overconfident; pelacarsen achieved roughly 40% Lp(a) reduction while olpasiran achieved over 90% reduction in Phase 2 data, and OCEAN(a) enrolled patients with baseline Lp(a) above 175 nanomoles per liter—a different population

→ vs aggressive: Risk-reward math uses spot price as reference point, embedding the assumption that today's close of 391 is the correct price for new information; if 391 is overshooting the fundamental shift, the so-called 9% downside is already substantially priced in and the asymmetry actually favors a fade of the move

→ vs aggressive: 40-50% trim plus tactical short creates concentration of risk—a leveraged directional bet on a single binary outcome with structural risk of being stopped on short while price drifts, resulting in smaller long at lower prices plus stopped-out short

→ vs conservative: Plan has no defined response to continued technical deterioration; if price prints lower lows at 385 and 378 and 50 SMA at 396.71 fails decisively on volume, the framework says nothing about that scenario

→ vs conservative: Imdelltra's 115% growth and Tezspire's Phase III win are real but if the Lp(a) read-across had not happened, AMGN would likely be trading above the August 25 high of 447; the floor is real but not currently operative

→ vs conservative: 25% trim underweights cumulative risk of Lp(a) class question, broken technical structure, and hostile macro environment; leaving 75% of position into a test of 200 SMA at 354.80 without acknowledging drawdown risk is insufficient